Welcome to our dedicated page for Goodrx Holdings SEC filings (Ticker: GDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GoodRx Holdings, Inc. filings document the financial reporting, governance, and public-company controls of a Nasdaq-listed digital healthcare platform for prescription savings. Its 8-K reports furnish quarterly operating results, revenue categories such as prescription transactions, subscriptions, and Pharma Direct, non-GAAP financial measures, and business outlook disclosures tied to medication access and pharmacy-market conditions.
GoodRx regulatory filings also cover proxy governance, board classification matters, director departures, officer appointments and resignations, executive compensation, equity awards under the 2020 Incentive Award Plan, and changes in the company’s independent registered public accounting firm.
McGinnis Christopher A reported acquisition or exercise transactions in this Form 4 filing.
GoodRx Holdings, Inc. reported that executive Christopher A. McGinnis received a grant of 443,852 restricted stock units on Class A common stock. Each unit represents a right to receive one share at no purchase price.
The restricted stock units vest in 12 equal quarterly installments, with the first vesting on April 15, 2026, and are subject to continued service through each vesting date. Following this award, McGinnis directly holds 126,321 shares of Class A common stock.
GoodRx Holdings, Inc. Chief Accounting Officer Romin Nabiey reported an equity compensation grant. On March 3, 2026, Nabiey acquired 108,189 restricted stock units, each representing a contingent right to receive one share of Class A common stock. These RSUs will vest in 12 equal quarterly installments, with the first vesting date on April 15, 2026, subject to continued service. Following this report, Nabiey held 175,748 shares of Class A common stock directly.
GoodRx Holdings, Inc. reported that director and officer Wendy Lynn Barnes acquired 1,331,557 restricted stock units on March 3, 2026 as an equity award. Each restricted stock unit represents a right to receive one share of Class A common stock.
The award will vest ratably in 12 equal quarterly installments, with the first vesting date on April 15, 2026, subject to her continued service through each vesting date. Following this award, she also held 427,993 shares of Class A common stock directly.
GoodRx Holdings, Inc. reported that board member Dipanjan Deb resigned from its Board of Directors, effective February 26, 2026. The company states that Mr. Deb’s decision to step down was not due to any disagreement with GoodRx or its management regarding operations, policies, or practices.
GoodRx Holdings, Inc. describes its business model as a consumer-focused digital healthcare platform that helps Americans find lower prices on prescription drugs and related services. The company’s core prescription transactions offering still generates most revenue, complemented by subscriptions, telehealth and pharma-direct advertising solutions.
GoodRx highlights a large estimated prescription and pharma-direct market opportunity of $600–$710 billion and positions its data-driven pricing engine, PBM and pharmacy relationships, and brand as key advantages. The filing also outlines significant risks, including PBM and retail pharmacy concentration, store closures, new federal initiatives like TrumpRx.gov, regulation of data privacy and telehealth, shifting cost burdens to consumers, and execution challenges as it expands offerings and manages growth.
GoodRx Holdings, Inc. reported fourth quarter 2025 revenue of $194.8 million and full year 2025 revenue of $796.9 million, up slightly from 2024. Full year net income rose to $30.4 million with a 3.8% net margin, while Adjusted EBITDA reached $270.5 million and a 33.9% margin. Growth was driven by a 41% increase in 2025 Pharma Direct revenue to $151.4 million, partly offset by declines in prescription transactions and subscription revenue. The company generated $167.9 million in operating cash flow, ended 2025 with $261.8 million in cash and $495.0 million of total debt, and repurchased 48.9 million Class A shares for $217.4 million. For 2026, management guides revenue to $750–$780 million and Adjusted EBITDA of more than $230 million, implying a year-over-year decline in both metrics while maintaining strong profitability.
McGinnis Christopher A reported multiple insider transaction types in a Form 4 filing for GDRX. The filing lists transactions totaling 411,039 shares at a weighted average price of $2.18 per share. Following the reported transactions, holdings were 537,359 shares.
GoodRx Holdings, Inc. Chief Accounting Officer Romin Nabiey reported equity award activity involving Class A common stock. On February 15, 2026, Nabiey exercised 4,804 restricted stock units, converting them into the same number of Class A shares at an exercise price of $0. In a related transaction coded "F," 1,979 Class A shares at $2.18 per share were disposed of to cover tax obligations, leaving 175,748 Class A shares held directly and 57,650 restricted stock units outstanding after these transactions.
GoodRx Holdings, Inc. Chief Accounting Officer Romin Nabiey reported RSU vesting and related share movements. On February 8, 2026, 12,663 restricted stock units converted into 12,663 shares of Class A common stock at an exercise price of $0.
On the same date, a Form 4 code “F” transaction reported the disposition of 5,215 Class A shares at $2.44 per share. Following these transactions, Nabiey beneficially owned 172,923 Class A common shares directly and 63,314 restricted stock units, each representing a right to receive one Class A share.
GoodRx Holdings director Scott Wagner reported the vesting of deferred stock units and corresponding common stock on January 21, 2026. A deferred stock unit award vested for 31,394 units, which corresponds to 31,394 shares of Class A common stock at an exercise price of $0. After this transaction, Wagner directly beneficially owned 62,788 deferred stock units and 216,663 shares of Class A common stock. The deferred stock units will settle in shares on the earliest of December 31, 2030, separation from service, a change in control, death, or disability, under the company’s Deferred Compensation Plan for Directors.